These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Storosum JG; van Zwieten BJ; Wohlfarth T; de Haan L; Khan A; van den Brink W Arch Gen Psychiatry; 2003 Apr; 60(4):365-8. PubMed ID: 12695313 [TBL] [Abstract][Full Text] [Related]
26. Ziprasidone, a new atypical antipsychotic drug. Carnahan RM; Lund BC; Perry PJ Pharmacotherapy; 2001 Jun; 21(6):717-30. PubMed ID: 11401184 [TBL] [Abstract][Full Text] [Related]
28. A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Arango C; Gómez-Beneyto M; Brenlla J; Gastó C; Sarramea-Crespo F; Chamorro L; Masramon X; Díez T; Eur Neuropsychopharmacol; 2007; 17(6-7):456-63. PubMed ID: 17234389 [TBL] [Abstract][Full Text] [Related]
29. Switching among antipsychotics in everyday clinical practice: focus on ziprasidone. Rossi A; Cañas F; Fagiolini A; Larmo I; Levy P; Montes JM; Papageorgiou G; Sturlason R; Zink M; Correll CU Postgrad Med; 2011 Jan; 123(1):135-59. PubMed ID: 21293094 [TBL] [Abstract][Full Text] [Related]
30. Ziprasidone monotherapy in bipolar II depression: an open trial. Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363 [TBL] [Abstract][Full Text] [Related]
31. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. Kane JM J Clin Psychiatry; 2003; 64 Suppl 19():19-25. PubMed ID: 14728086 [TBL] [Abstract][Full Text] [Related]
32. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. Harvey PD; Endicott JM; Loebel AD Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505 [TBL] [Abstract][Full Text] [Related]
33. The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia. Isaac M; Koch A Eur Neuropsychopharmacol; 2010 Mar; 20(3):139-45. PubMed ID: 20053539 [TBL] [Abstract][Full Text] [Related]
34. Epidemiologic study of aripiprazole use and the incidence of suicide events. Ulcickas Yood M; Delorenze G; Quesenberry CP; Tsai AL; Phillips S; Willey VJ; Niemcryk SJ; Wells K; Skovron ML; Cziraky MJ; Carson W; Oliveria SA Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1124-30. PubMed ID: 20925132 [TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. Tourian KA; Padmanabhan K; Groark J; Ninan PT J Clin Psychopharmacol; 2010 Aug; 30(4):411-6. PubMed ID: 20631558 [TBL] [Abstract][Full Text] [Related]
36. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Tollefson GD; Rampey AH; Beasley CM; Enas GG; Potvin JH J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412 [TBL] [Abstract][Full Text] [Related]
37. Tardive dyskinesia and ziprasidone. Rosenquist KJ; Walker SS; Ghaemi SN Am J Psychiatry; 2002 Aug; 159(8):1436. PubMed ID: 12153846 [No Abstract] [Full Text] [Related]
39. Methodological concerns in a trial of ziprasidone and olanzapine. Ross DE Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994735 [No Abstract] [Full Text] [Related]
40. Methodological issues in a comparative study of ziprasidone and risperidone. Gharabawi GM; Bossie CA; Mahmoud R; Canuso CM; Lasser RA; Turkoz I; Greenspan A J Clin Psychiatry; 2006 Jan; 67(1):162-3; author reply 163-4. PubMed ID: 16426103 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]